Fig. 5

TFBP partially improved motor functions after TBI. In the beam walking test, CCI- challenged mice showed an increase in average time needed to traverse the beam (A), as well as in immobility time spent on the beam (B). TFBP (16.25 mg/kg and 32.5 mg/kg, i.p.), especially at the highest tested dose, mitigated this injury-induced increase, as seen in the behavioral assessment performed after 1 week. (A, B). Gait analysis was performed through DiGi Gait System (Mouse Specifics, Inc.). Treatment with TFBP (HD, high dose) countered the TBI-induced increase in brake time (time between initial paw contact to maximum paw contact), 1 week post injury (C). *p < 0.05, ***p < 0.001 vs control group; ^#p < 0.05, ^##p < 0.01, ^###p < 0.001 vs CCI group). ‘N value of animals’ shown at the base of each bar within brackets